Background: Bulevirtide (BLV) monotherapy for up to 144 weeks was safe and effective in patients with chronic hepatitis D (CHD) in a phase III trial, but long-term real-world data are limited. We evaluated its effectiveness and safety in patients with HDV-related cirrhosis in clinical practice.Methods: Consecutive patients with HDV-related cirrhosis treated with BLV 2 mg/day… Continue reading Effectiveness and safety of three years of bulevirtide monotherapy in patients with HDV-related compensated cirrhosis: the Italian compassionate use program
